Product information and disease description Place of product in therapy Disease description Epidemiology

Incidence of Open-angle glaucoma or ocular hypertension

5 evidence topics · 5 sources

Global incidence: systematic review and meta-analysis of prospective studies

“A total of 9050 articles were identified in literature search, and 50 articles provided incidence data of glaucoma subtypes. In 2022, the global incidence rate of POAG was 23.46 (95% confidence interval (CI) = 15.68-32.91) per 10 000 person-years among 40-79 years.” (opens the source at this quote in a new tab)
“The pooled ACI of POAG was 0.21% (95% CI = 0.13%-0.30%).” (opens the source at this quote in a new tab)

United States incidence: Medicare fee-for-service beneficiaries, 2017 to 2021

“From 2017 to 2021, 5.5-6.2% of Medicare FFS beneficiaries were identified with prevalent POAG, with ~1% categorized as incident.” (opens the source at this quote in a new tab)

United States incidence: Olmsted County, Minnesota

“The overall age- and gender-adjusted annual incidence rate of OAG in a predominantly Caucasian population is conservatively estimated to be 14.5 per 100,000 population. The rates increased with age from 1.6 in the fourth decade of life to 94.3 in the eighth decade.” (opens the source at this quote in a new tab)

United States incidence of open-angle glaucoma and ocular hypertension: Los Angeles Latino Eye Study

“Among the 3939 participants (mean age, 54.7 ± 10.5 years) with complete data for a diagnosis of glaucoma at both baseline and follow-up examination, incident OAG at the 4-year follow-up was identified in 87 persons (4-year incidence rate, 2.3%; 95% confidence interval, 1.8% to 2.8%). Incident OHT at the 4-year follow-up was identified in 124 persons (4-year incidence rate, 3.5%; 95% confidence interval, 2.9% to 4.1%).” (opens the source at this quote in a new tab)

Incidence of primary open-angle glaucoma among individuals with ocular hypertension: Ocular Hypertension Treatment Study, 20-year follow-up

“A total of 1636 individuals (mean [SD] age, 55.4 [9.6] years; 931 women [56.9%]; 1138 White participants [69.6%]; 407 Black/African American participants [24.9%]) were randomized in phase 1 of the clinical trial. Of those, 483 participants (29.5%) developed POAG in 1 or both eyes (unadjusted incidence). After adjusting for exposure time, the 20-year cumulative incidence of POAG in 1 or both eyes was 45.6% (95% CI, 42.3%-48.8%) among all participants, 49.3% (95% CI, 44.5%-53.8%) among participants in the observation group, and 41.9% (95% CI, 37.2%-46.3%) among participants in the medication group.” (opens the source at this quote in a new tab)